Kennedy Capital Management, Inc. Avrobio, Inc. Transaction History

Kennedy Capital Management, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.29 - $4.04 $125,900 - $394,291	-97,597 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$3.45 - $6.05 $10,722 - $18,803	-3,108 Reduced 3.09%	97,597 $376,000
Q3 2021 Nov 15, 2021	BUY	$5.53 - $9.28 $7,144 - $11,989	1,292 Added 1.3%	100,705 $562,000
Q2 2021 Aug 16, 2021	SELL	$7.84 - $12.6 $32,755 - $52,642	-4,178 Reduced 4.03%	99,413 $884,000
Q1 2021 May 14, 2021	SELL	$10.54 - $19.3 $847,521 - $1.55 Million	-80,410 Reduced 43.7%	103,591 $1.32 Million
Q4 2020 Feb 12, 2021	BUY	$12.79 - $17.1 $740,515 - $990,055	57,898 Added 45.91%	184,001 $2.57 Million
Q3 2020 Nov 16, 2020	SELL	$12.99 - $19.41 $24,875 - $37,170	-1,915 Reduced 1.5%	126,103 $1.64 Million
Q2 2020 Aug 14, 2020	BUY	$12.19 - $22.96 $69,580 - $131,055	5,708 Added 4.67%	128,018 $2.23 Million
Q1 2020 May 15, 2020	SELL	$10.08 - $27.21 $417,664 - $1.13 Million	-41,435 Reduced 25.3%	122,310 $1.9 Million
Q4 2019 Feb 14, 2020	BUY	$13.05 - $21.88 $2.14 Million - $3.58 Million	163,745 New	163,745 $3.3 Million

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.